Bio-Gene Technology (ASX: $BGT) Half Year Report Overview

Bio-Gene Technology Limited (ASX: $BGT) presents its financial results for the six months ended 31 December 2023. The company achieved several key milestones during this period, including a major review of product opportunities, signing a Development and Licence Agreement with STK Bio-Ag Technologies, and being selected for a US$10 million research program funded by the US Centers for Disease Control and Prevention.

Executive Commentary on Half Year Report

Over the first half of FY24, Bio-Gene strengthened its focus on commercialising products to meet the global challenge of insecticide resistance. The Company consolidated commercial and research partnerships to progress registration of two active ingredients, Qcide and Flavocide®, and undertook a strategic review to target its pipeline on products with the greatest commercial applications across public health vector control, crop protection, and consumer use. Changes to the Board and Executive team were made during the half to help drive the increasing focus on commercialisation.

Summary of Half Year Report and Outlook

Bio-Gene Technology (ASX: $BGT) achieved significant progress in the first half of FY24, focusing on commercializing insecticides to address the global challenge of insecticide resistance. The Company strengthened its commercial and research partnerships, targeting products with the greatest commercial applications across various sectors. With a strategic review and key milestones achieved, Bio-Gene is well-positioned to advance its product pipeline and meet the increasing demand for its botanically derived insecticides.